The Food and Drug Administration recently launched a Bad Ad Program. The campaign is intended to educate providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading. The program will be rolled out in three phases. In Phase 1, the program will engage healthcare providers at specifically-selected medical conventions and partner with specific medical societies to distribute educational materials. Phases 2 and 3 will expand the FDA’s collaborative efforts and update the educational materials developed for Phase 1. The agency is leaving open the possibility of expanding the effort into other health-related products.
